Physician profile
Chike Nzerue
NPI 1912976762
$94,687.29
in general payments reported to CMS, 2019-2025
12 companies · $37K in 2025
The $37K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2021: $227 · 2023: $29K · 2024: $28K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $66K · Travel and Lodging: $24K · Food and Beverage: $3,867 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $66,318.75 |
| Travel and Lodging | $24,126.73 |
| Food and Beverage | $3,866.66 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $93,654.01 | 2023-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $402.51 | 2021-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $123.41 | 2019 | |
| Novo Nordisk INC | $121.30 | 2024 | |
| Amgen INC. | $118.69 | 2025 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.59 | 2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $54.15 | 2025 | Lupkynis |
| Genentech USA, INC. | $46.00 | 2025 | Gazyva |
| Vertex Pharmaceuticals Incorporated | $35.00 | 2025 | |
| Horizon Therapeutics Plc | $28.10 | 2023 | Krystexxa |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Hologic Sales and Service, LLC | $22.92 | 2025 | Aptima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chike Nzerue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.